Aktie A2QP1Y SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen SciClone Pharmaceuticals (Holdings) Limited

Aktien

A2QP1Y

KYG4271B1023

6600

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:22 20.06.2024 		% 5 Tage % 1. Jan.
18,72 HKD +0,86 % Intraday Chart für SciClone Pharmaceuticals (Holdings) Limited -.--% +34,48 %
26.06. SciClone Pharmaceuticals (Holdings) Limited kündigt Rücktritt von Wang Haixia als nicht-geschäftsführendes Verwaltungsratsmitglied an CI
01.04. SciClone Pharmaceuticals verzeichnet 31% Gewinnanstieg im Jahr 2023 MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
SciClone Pharmaceuticals Limited Announces Retirement of Wang Haixia as Non-Executive Director
SciClone Pharmaceuticals Limited(SEHK:6600) dropped from S&P Global BMI Index
Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong
Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit
Sciclone Pharmaceuticals Limited Announces Executive Changes
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023
GL China Opportunities Fund IV L.P. and GL China Opportunities Fund IV L.P., managed by GL Capital Group and GL Capital Management GP L.P. agreed to acquire 66.69% stake in SciClone Pharmaceuticals Limited for HKD 7.9 billion.
SciClone Completes Patient Enrollment for Urinary Tract Infection Drug's Phase 3 Trial; Shares Rise 3%
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
SciClone Signs Licensing Deal with Menarini for Breast Cancer Drug; Shares Rise 3%
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023
SciClone Pharmaceuticals Doses First Patient in Phase 3 Study for Urinary Tract Infection Injection
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China
SciClone Commercially Launches Neuroblastoma Treatment in China
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QP1Y Aktie
  4. Nachrichten SciClone Pharmaceuticals (Holdings) Limited
  5. Andere Sprachen